Biopharmaceutical Company Secures Dismissal in Stock Drop Matter

Secured a dismissal on behalf of a a biopharmaceutical company focused on innovative anti-cancer agents, in a shareholder class action following a 70 percent drop of our client’s stock. The plaintiffs claimed our client failed to disclose that a new drug application submitted to the FDA for a lung cancer treatment, contained immature data sets with a lower than expected number of patients responding to the treatment. This matter involved several lawsuits in state and federal courts in Colorado, Delaware, and California.